US-based biotech Eikon Therapeutics has raised $350.7m in funding to advance its portfolio of cancer candidates. The company’s lead asset, EIK1001, is a systemically administered Toll-like receptor 7 ...
Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived ...
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to ...
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus ...
Eikon Therapeutics has added to its already copious cash reserves with a $351 million fourth-round financing to fund a rapidly expanding clinical pipeline of cancer therapies. The start-up – helmed by ...
This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. Created by Cambridge-based TAB U.K., TAB Dashboard is the world’s most ...
View Eikon Therapeutics stock forecast data, including EIKN stock price estimates and 12-month Eikon Therapeutics price targets, to assess potential upside or downside. Compare EIKN analyst ratings to ...
Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...
HAYWARD, Calif., March 23, 2022--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results